Brief: Zealand Pharma Says Phase 2 Zupreme-1 Trial Met Its Primary Endpoint
05/06/2026 21:45
BRIEF-Zealand Pharma Says Phase 2 Zupreme-1 Trial Met Its Primary Endpoint June 6 (Reuters) - Zealand Pharma A/S ZELA.CO:
ZEALAND PHARMA: PETRELINTIDE LED TO MEAN REDUCTIONS IN BODY WEIGHT FROM BASELINE TO WEEK 42 OF UP TO 10.7% VERSUS 1.7% FOR PLACEBO
ZEALAND PHARMA: PHASE 2 ZUPREME-1 TRIAL MET ITS PRIMARY ENDPOINT
ZEALAND PHARMA: PHASE 2 ZUPREME-1 TRIAL SHOWS CLINICALLY MEANINGFUL, DOUBLE-DIGIT WEIGHT LOSS IN PARTICIPANTS THROUGH WEEK 42
ZEALAND PHARMA: PHASE 3 TRIALS FOR CHRONIC WEIGHT MANAGEMENT PLANNED FOR INITIATION IN H2 2026
ZEALAND PHARMA: ONLY 1.5% OF PARTICIPANTS DISCONTINUED PETRELINTIDE DUE TO GASTROINTESTINAL AES, NO UNEXPECTED SAFETY FINDINGS
Further company coverage: ZELA.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)